Molecular diagnostic company Immunexpress has received the CE Mark in Europe to market and sell its rapid sepsis test.
The test combines the company's SeptiCyte technology with Biocartis' Idylla platform and provides results in an hour. The reverse transcription polymerase chain reaction (RT-PCR) test is a gene expression assay that quantifies the relative expression levels of host response genes isolated from whole blood collected in the PAXgene blood RNA tube, according to the company.
Immunexpress established a long-term commercialization partnership for the test with Biocartis and plans to immediately initiate operations to make SeptiCyte Rapid available on Idylla systems in Europe. The company believes the test will be useful during the COVID-19 pandemic for the early identification of patients at risk for developing complications associated with sepsis.
